Welcome to our dedicated page for KALA BIO SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KALA BIO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KALA BIO's regulatory disclosures and financial reporting.
KALA BIO filed a Form 12b-25, notifying a delay in its Form 10-Q for the quarter ended September 30, 2025, citing that timely filing was not possible without unreasonable effort or expense. The company states it will file no later than the fifth calendar day after the due date.
The delay follows a default under its Loan and Security Agreement with Oxford Finance, after which Oxford declared all obligations immediately due, swept substantially all cash, and indicated plans to foreclose on assets. On October 19, the board terminated all remaining employees not required for foreclosure activities, which hindered preparation of the 10-Q.
On November 3, Oxford paused foreclosure and permitted use of $125,000 from swept funds to negotiate financing and begin 10-Q work. On November 9, KALA entered a Convertible Loan Agreement with an individual investor for up to $375,000, a portion of which may be used to prepare and file the 10-Q.
KALA BIO reported it received a Nasdaq deficiency notice for failing to meet the Nasdaq Capital Market’s market value of listed securities requirement. The company’s market value was below $35 million for 30 consecutive business days, triggering noncompliance with Listing Rule 5550(b)(2).
Nasdaq granted a 180‑day cure period until May 11, 2026. Compliance is regained if the market value closes at $35 million or more for at least 10 consecutive business days before the deadline. The filing also notes KALA BIO does not meet the alternative continued listing standards of stockholders’ equity of at least $2.5 million or net income from continuing operations of at least $500,000 in the relevant periods.
If compliance is not restored by the deadline, the company may receive a delisting notice and could appeal to a Nasdaq Listing Qualifications Panel. KALA BIO plans to monitor its market value and may consider options to regain compliance.
KALA Bio entered a Convertible Loan Agreement with an individual investor for up to $375,000, split into two fundings of $187,500 each targeted for November 10 and November 12, 2025. The loan carries 15% simple annual interest, payable monthly starting in December 2025, and matures one year after funding, with a potential one-year extension under specified conditions.
The lender may convert outstanding amounts into common stock at prices set in the agreement, and, ahead of an M&A transaction or underwritten public offering, may elect to convert into the most senior class of shares or require cash repayment. KALA can prepay anytime with three business days’ notice, during which the lender may choose to convert.
Proceeds are limited to negotiating a further investment with the lender and preparing the Form 10‑Q for the quarter ended September 30, 2025; KALA agreed to exclusivity through November 17, 2025. Oxford Finance previously swept substantially all cash and signaled foreclosure, then paused and allowed $125,000 to fund this process; foreclosure may resume absent additional financing.
KALA BIO (KALA) disclosed an insider transaction by a director. On 10/23/2025, the reporting person sold 154,894 shares of common stock at a $0.81 weighted average price, with individual trades executed between $0.78 and $0.85. Following the sale, the reporting person beneficially owns 103,540 shares, reported as unvested RSUs, held directly.
The filing notes the price is a weighted average and that detailed trade breakdowns within the stated range are available upon request.
KALA BIO (KALA) reported insider transactions by its Chief Financial Officer, Mary Reumuth. On 10/22/2025, she sold 32,230 shares of common stock at a weighted average price of $0.83, with individual trades ranging from $0.82 to $0.84. On 10/23/2025, she sold an additional 967 shares at $0.82.
Following these transactions, her reported beneficial ownership was 29,873 shares after the first sale and 28,906 shares after the second sale, held directly. A footnote states the 28,906 balance includes unvested RSUs.
KALA BIO (KALA) reported an insider stock transaction on a Form 4. A director sold 47,768 shares of common stock on 10/22/2025 at a weighted average price of $0.83, with individual trades ranging from $0.82 to $0.85.
After the sale, the reporting person beneficially owned 35,932 shares directly, which includes 35,732 unvested RSUs, and 1 share indirectly held by a son.
KALA BIO (KALA) reported a Form 4 showing an officer transaction. On 10/22/2025, an officer sold 46,748 shares of common stock at a weighted average price of $0.83, with trade prices ranging from $0.82 to $0.85. Following the sale, 35,952 shares were listed as beneficially owned. A footnote states this figure includes 35,952 unvested RSUs. The reporting person’s role is noted as Head of Research and Development and Chief Medical Officer, and the ownership form is Direct.
KALA BIO (KALA) reported an insider transaction by its Chief Business Officer. On 10/22/2025, the officer sold 20,806 shares of common stock at a $0.83 weighted average price, with trades ranging from $0.82 to $0.84. Following the sale, the officer beneficially owned 41,760 shares directly.
The reported balance includes 28,878 unvested RSUs, which are awards that may settle in shares as they vest. The filing lists direct ownership and does not indicate joint or group filing.
Baker Bros. Advisors LP and affiliated filers report beneficial ownership of 744,759 shares of KALA BIO, Inc. common stock, representing 9.99% of the outstanding shares based on a 7,021,040 share base as of August 7, 2025 plus convertible preferred shares. The holdings include 434,200 shares issuable upon conversion of 4,342 Series E preferred shares; conversion of convertible preferred is subject to a 9.99% beneficial ownership limitation (increaseable to 19.99% with 61 days' notice). The filers state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control; prior nomination rights under a purchase agreement were reported as no longer held as of October 2, 2025.
Baker Bros. reporting persons filed a Form 4 disclosing multiple sales of KALA BIO, Inc. (KALA) common stock on 09/30/2025 and 10/01/2025. The filing shows four separate dispositions: 21,376 and 195,425 shares on 09/30/2025 at a weighted average price of $1.5959, and 50,640 and 462,967 shares on 10/01/2025 at a weighted average price of $1.3838. After each reported transaction, the filings list the number of shares beneficially owned by the reporting entities and individuals on an indirect basis. Footnotes state the trading occurred through the Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) across price ranges of $1.50–$1.84 and $1.27–$1.48, and clarify the Adviser and certain partners disclaim beneficial ownership except for pecuniary interest.